Contact the Editorial Team

Editorial correspondence

Agility Peptide welcomes correspondence on the research record: a citation we have quoted inaccurately, a regulatory reference that has become outdated, or a peer-reviewed study about BPC-157, TB-500, GHK-Cu or KLOW (or any of KLOW's four component peptides) that should be added to the references page. Corrections that improve the accuracy of the digest are the most useful messages we receive.

The most actionable notes specify three things: the page they refer to, the exact passage in question, and the supporting citation — a DOI or PubMed ID wherever possible. That allows us to verify a proposed change against the source directly.

Editorial mailbox: editors@agilitypeptide.com

What this reference cannot do

So that no message goes unanswered for the wrong reason, a few things fall outside what this site can address. Agility Peptide is a literature digest, not a clinic or a vendor, so we cannot:

• Advise on, recommend, or comment on human use of any peptide discussed here.
• Suggest a dose, schedule, or route of administration for any individual.
• Diagnose a condition or assess whether a research finding applies to a specific person.
• Sell, source, recommend, or help locate any compound from any supplier.
• Answer requests from athletes regarding these compounds given that BPC-157 (WADA S0) and TB-500 / the KLOW blend (WADA S2) are prohibited in sport.

Readers seeking clinical guidance should consult a licensed clinician in their own jurisdiction. Responses to editorial correspondence are not guaranteed and may be delayed; the mailbox is monitored intermittently.